<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574713</url>
  </required_header>
  <id_info>
    <org_study_id>63527</org_study_id>
    <secondary_id>2019-003386-18</secondary_id>
    <secondary_id>NFR 288699.</secondary_id>
    <nct_id>NCT04574713</nct_id>
  </id_info>
  <brief_title>Candesartan for Migraine Prevention:</brief_title>
  <acronym>CandMig-3</acronym>
  <official_title>Candesartan for Migraine Prevention: A Multicentre, Binational, Triple Blind, Placebo Controlled, Parallel Group Study of Two Doses of Candesartan (8 and 16 mg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Molde Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rikshospitalet University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tartu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to see whether the favorable preventative effect of&#xD;
      candesartan 16 mg per day in episodic migraine, that was found previously in two smaller&#xD;
      randomized controlled cross-over studies, can be confirmed in a larger, multicenter,&#xD;
      randomized controlled parallel group study. In addition it will be investigated whether 1)&#xD;
      also a smaller dose of 8 mg is effective, and 2) whether the favorable side effect profile,&#xD;
      seen in previous studies, can be confirmed, and whether it is even better with the smaller&#xD;
      dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multicentre, binational, triple blind, placebo controlled, parallel group study of two doses</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in number of migraine days per 4 weeks, from baseline</measure>
    <time_frame>20 weeks plus final visit 1 week after treatment</time_frame>
    <description>participants will fill in a headache diary during 20 weeks treatment</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Candesartan 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan 16 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Oral Tablet 8 mg</intervention_name>
    <description>1 over-encapsulated tablet once daily, containing candesartan 8 mg, for 12 weeks (84 days).</description>
    <arm_group_label>Candesartan 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Oral Tablet 16 mg</intervention_name>
    <description>1 over-encapsulated tablet once daily, containing candesartan 16 mg, for 12 weeks (84 days).</description>
    <arm_group_label>Candesartan 16 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>1 over-encapsulated tablet once daily, containing placebo, for 12 weeks (84 days).</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Episodic migraine with or without aura according to ICHD-3 criteria&#xD;
&#xD;
          3. At inclusion, patients should retrospectively have from 2 to 8 migraine attacks per&#xD;
             month during the last 3 months. This frequency must be confirmed in the headache diary&#xD;
             before randomization to treatment.&#xD;
&#xD;
          4. Debut of migraine at least one year prior to inclusion&#xD;
&#xD;
          5. Start of migraine before age 50 years&#xD;
&#xD;
          6. No use of other migraine prophylactics during the study&#xD;
&#xD;
          7. For women of child-bearing potential, use of highly effective contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Interval headache not distinguishable from migraine;&#xD;
&#xD;
          2. Chronic migraine, chronic tension-type headache, medication overuse headache or other&#xD;
             headache occurring on ≥ 15 days/month&#xD;
&#xD;
          3. Pregnancy, planning to get pregnant, inability to use contraceptives, lactating&#xD;
&#xD;
          4. Clinical information on or signs of cholestasis or decreased hepatic or renal&#xD;
             function. If in doubt, relevant blood tests should be performed&#xD;
&#xD;
          5. High degree of comorbidity and/or frailty associated with reduced life expectancy or&#xD;
             high likelihood of hospitalization, at the discretion of the investigator&#xD;
&#xD;
          6. Hypersensitivity to candesartan&#xD;
&#xD;
          7. History of angioneurotic oedema&#xD;
&#xD;
          8. Current use of antihypertensive medication&#xD;
&#xD;
          9. Current use of potassium supplements&#xD;
&#xD;
         10. Current use of spironolactone&#xD;
&#xD;
         11. Primary hyperaldosteronism (Conn's syndrome)&#xD;
&#xD;
         12. Significant psychiatric illness&#xD;
&#xD;
         13. Use of medicines for migraine prophylaxis less than 4 weeks, or of botulinum toxin&#xD;
             less than 16 weeks, prior to start of study&#xD;
&#xD;
         14. Having tried ≥ 3 prophylactic drugs against migraine during the last 10 years&#xD;
&#xD;
         15. Previous use of candesartan&#xD;
&#xD;
         16. Requiring detoxification from acute medication (triptans, opioids)&#xD;
&#xD;
         17. Consistently failing to respond to any acute migraine medication&#xD;
&#xD;
         18. Alcohol or illicit drug dependence.&#xD;
&#xD;
         19. Inability to understand study procedures and to comply with them for the entire length&#xD;
             of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Samsonsen, md phd</last_name>
    <role>Study Director</role>
    <affiliation>St Olavs Hospital, Dept Neurology &amp; Clinical Neurophysiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorunn L Helbostad, prof</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology, Fac MH, Dept INB</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erling Tronvik, md prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian University of Science and Technology, Fac MH, Dept INB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erling Tronvik, md prof</last_name>
    <phone>+47 40458528</phone>
    <email>erling.tronvik@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lise Rystad Øie, phd</last_name>
    <email>lise.r.oie@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tartu University Clinics</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Braschinsky, md phd</last_name>
      <email>mark.braschinsky@kliinikum.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marthe-Helene Bjørk, md phd</last_name>
      <email>Marte.Bjork@uib.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordland Hospital</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Bjørnar Alstadhaug, md phd</last_name>
      <email>Karl.Bjornar.Alstadhaug@nordlandssykehuset.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sørlandet Hospital</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magne Geir Bøe, md phd</last_name>
      <email>magne.geir.boe@sshf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital AHUS</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christofer Lundqvist, md phd</last_name>
      <email>christofer.lundqvist@ahus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Møre and Romsdal Hospital Molde</name>
      <address>
        <city>Molde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Müller, md phd</last_name>
      <email>Bernd.Muller@helse-mr.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Hege Aamodt, md phd</last_name>
      <email>anhaam@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ullevål University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bendik Winsvold, md phd</last_name>
      <email>UXWINB@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Ivar Müller, md phd</last_name>
      <email>Kai.Ivar.Muller@unn.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erling Tronvik, md phd</last_name>
      <email>erling.tronvik@ntnu.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention and Control</keyword>
  <keyword>Candesartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

